Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ESCALADARA: Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma

NCT04150692 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04150692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ESCALADARA: Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
January 8, 2021
Completion date
March 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma